{"id":1381,"date":"2015-11-12T18:05:22","date_gmt":"2015-11-12T16:05:22","guid":{"rendered":"http:\/\/lupusgalicia.org\/?p=1381"},"modified":"2015-11-12T18:05:22","modified_gmt":"2015-11-12T16:05:22","slug":"gsk-anuncia-resultados-positivos-de-benlysta-en-su-fase-iii","status":"publish","type":"post","link":"https:\/\/lupusgalicia.org\/?p=1381","title":{"rendered":"GSK anuncia resultados positivos de Benlysta\u00ae en su fase III"},"content":{"rendered":"<h1 style=\"text-align: center;\"><span style=\"color: #800080;\"><strong>GSK anuncia resultados positivos de su ensayo fase III BLISS-SC de Benlysta\u00ae (belimumab) administrado por v\u00eda subcut\u00e1nea en pacientes con lupus eritematoso sist\u00e9mico (LES)<\/strong><\/span><\/h1>\n<p><a href=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-1382 aligncenter\" src=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-300x159.jpg\" alt=\"3078a28c6feb1f9e408af5e3811698e1_XL\" width=\"300\" height=\"159\" srcset=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-300x159.jpg 300w, https:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-500x266.jpg 500w, https:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL.jpg 900w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>GSK ha anunciado resultados del ensayo cl\u00ednico pivotal fase III BLISS-SC en pacientes con lupus eritematoso sist\u00e9mico (LES) activo. Estos resultados, que se han presentado en la Reuni\u00f3n Anual del American College of Rheumatology\/ Association for Rheumatology Health Professionals, muestran que Benlysta\u00ae (belimumab) 200 mg administrado de forma semanal por v\u00eda subcut\u00e1nea m\u00e1s terapia est\u00e1ndar (TE) muestra una reducci\u00f3n significativamente mayor en la actividad de la enfermedad que placebo m\u00e1s TE.<\/p>\n<p><img decoding=\"async\" src=\"http:\/\/www.pmfarma.es\/noticias\/noticias\/21786\/image\/benlysta.jpg\" alt=\"\" \/>\u00a0 \u00a0\u00a0En lo que respecta a la variable principal de eficacia (\u00edndice de respuesta de lupus eritematoso sist\u00e9mico (SRI, por sus siglas en ingl\u00e9s) en la semana 52), un n\u00famero significativamente mayor de pacientes tratados con belimumab administrado por v\u00eda subcut\u00e1nea m\u00e1s TE (60,8%) mostraron reducci\u00f3n en la actividad de la enfermedad en comparaci\u00f3n con placebo m\u00e1s TE (48,47%, p=0,0011). El SRI es un criterio completo de valoraci\u00f3n compuesto, utilizado en el programa de ensayos cl\u00ednicos pivotales de fase III BLISS para belimumab administrado mediante perfusi\u00f3n intravenosa. Los componentes del SRI miden la reducci\u00f3n en la actividad de la enfermedad, definida como mejor\u00eda cl\u00ednica (SELENA-SLEDAI) sin empeoramiento significativo en ning\u00fan sistema de \u00f3rganos (BILAG) y sin empeoramiento en la valoraci\u00f3n global del m\u00e9dico (PGA).<br \/>\nA pesar de utilizar la terapia est\u00e1ndar habitual, como glucocorticosteroides e inmunosupresores, alrededor del 60 por ciento de los pacientes de lupus contin\u00faan experimentando s\u00edntomas persistentes y exacerbaciones graves de la enfermedad.<\/p>\n<p><span style=\"color: #800080;\"><em>\u00abEste es el tercer ensayo cl\u00ednico fase III de belimumab en pacientes con lupus realizado con \u00e9xito por GSK, y sus resultados refuerzan nuestra creencia en la v\u00eda del BLyS como una forma de reducir la actividad subyacente de la enfermedad<\/em><\/span>\u00ab, advierte Paul-Peter Tak, vicepresidente senior y jefe de la unidad del \u00e1rea terap\u00e9utica de inmuno-inflamaci\u00f3n en GSK.<\/p>\n<p>En base a estos datos se iniciar\u00e1n las solicitudes de aprobaci\u00f3n a nivel mundial para una formulaci\u00f3n subcut\u00e1nea de belimumab, que proporcionar\u00eda a los pacientes id\u00f3neos una nueva aproximaci\u00f3n a la administraci\u00f3n del tratamiento.<\/p>\n<p>Actualmente, &#8216;Benlysta&#8217; est\u00e1 indicado en Estados Unidos\u00a0para el tratamiento de pacientes adultos con lupus eritematoso sist\u00e9mico (LES) activo, con autoanticuerpos positivos, que est\u00e9n recibiendo tratamiento est\u00e1ndar.<\/p>\n<p><a href=\"http:\/\/www.pmfarma.es\/noticias\/21786-gsk-anuncia-resultados-positivos-de-su-ensayo-fase-iii-bliss-sc-de-benlysta.html\">PMPHARMA<\/a><\/p>\n<p><a href=\"http:\/\/www.medicalnewstoday.com\/releases\/302462.php\">Medical News Today<\/a><\/p>\n<p><a href=\"http:\/\/noticias.lainformacion.com\/salud\/terapia\/gsk-anuncia-resultados-positivos-de-benlysta-para-lupus-eritematoso-sistemico_Rwoo30TTk4p443qAMJxb2\/\">Europa Press<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GSK anuncia resultados positivos de su ensayo fase III BLISS-SC de Benlysta\u00ae (belimumab) administrado por v\u00eda subcut\u00e1nea en pacientes con lupus eritematoso sist\u00e9mico (LES) GSK ha anunciado resultados del ensayo cl\u00ednico pivotal fase III BLISS-SC en pacientes con lupus eritematoso sist\u00e9mico (LES) activo. Estos resultados, que se han presentado en la Reuni\u00f3n Anual del American [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[6,5],"tags":[36,48,16],"class_list":["post-1381","post","type-post","status-publish","format-standard","hentry","category-investigacion","category-lupus-internacional","tag-belibumab","tag-benlysta","tag-tratamientos"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\r\n<title>GSK anuncia resultados positivos de Benlysta\u00ae en su fase III - Asociaci\u00f3n Galega de Lupus<\/title>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/lupusgalicia.org\/?p=1381\" \/>\r\n<meta property=\"og:locale\" content=\"es_ES\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"GSK anuncia resultados positivos de Benlysta\u00ae en su fase III - Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"og:description\" content=\"GSK anuncia resultados positivos de su ensayo fase III BLISS-SC de Benlysta\u00ae (belimumab) administrado por v\u00eda subcut\u00e1nea en pacientes con lupus eritematoso sist\u00e9mico (LES) GSK ha anunciado resultados del ensayo cl\u00ednico pivotal fase III BLISS-SC en pacientes con lupus eritematoso sist\u00e9mico (LES) activo. Estos resultados, que se han presentado en la Reuni\u00f3n Anual del American [&hellip;]\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/lupusgalicia.org\/?p=1381\" \/>\r\n<meta property=\"og:site_name\" content=\"Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LupusGalicia\/\" \/>\r\n<meta property=\"article:published_time\" content=\"2015-11-12T16:05:22+00:00\" \/>\r\n<meta property=\"og:image\" content=\"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-300x159.jpg\" \/>\r\n<meta name=\"author\" content=\"Agal\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:creator\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:site\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Agal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=1381#article\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=1381\"},\"author\":{\"name\":\"Agal\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\"},\"headline\":\"GSK anuncia resultados positivos de Benlysta\u00ae en su fase III\",\"datePublished\":\"2015-11-12T16:05:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=1381\"},\"wordCount\":428,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=1381#primaryimage\"},\"thumbnailUrl\":\"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-300x159.jpg\",\"keywords\":[\"Belibumab\",\"Benlysta\",\"Tratamientos\"],\"articleSection\":[\"Investigaci\u00f3n\",\"Lupus Internacional\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=1381#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=1381\",\"url\":\"https:\/\/lupusgalicia.org\/?p=1381\",\"name\":\"GSK anuncia resultados positivos de Benlysta\u00ae en su fase III - Asociaci\u00f3n Galega de Lupus\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=1381#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=1381#primaryimage\"},\"thumbnailUrl\":\"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-300x159.jpg\",\"datePublished\":\"2015-11-12T16:05:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=1381#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=1381\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=1381#primaryimage\",\"url\":\"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-300x159.jpg\",\"contentUrl\":\"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-300x159.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=1381#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/lupusgalicia.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK anuncia resultados positivos de Benlysta\u00ae en su fase III\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lupusgalicia.org\/#website\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"description\":\"Trabajando para y por las personas con Lupus\",\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lupusgalicia.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lupusgalicia.org\/#organization\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"width\":2560,\"height\":2522,\"caption\":\"Asociaci\u00f3n Galega de Lupus\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LupusGalicia\/\",\"https:\/\/x.com\/LupusGalicia\",\"https:\/\/www.instagram.com\/lupusgalicia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\",\"name\":\"Agal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"caption\":\"Agal\"},\"description\":\"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...\",\"sameAs\":[\"http:\/\/www.lupusgalicia.org\"],\"url\":\"https:\/\/lupusgalicia.org\/?author=1\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GSK anuncia resultados positivos de Benlysta\u00ae en su fase III - Asociaci\u00f3n Galega de Lupus","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lupusgalicia.org\/?p=1381","og_locale":"es_ES","og_type":"article","og_title":"GSK anuncia resultados positivos de Benlysta\u00ae en su fase III - Asociaci\u00f3n Galega de Lupus","og_description":"GSK anuncia resultados positivos de su ensayo fase III BLISS-SC de Benlysta\u00ae (belimumab) administrado por v\u00eda subcut\u00e1nea en pacientes con lupus eritematoso sist\u00e9mico (LES) GSK ha anunciado resultados del ensayo cl\u00ednico pivotal fase III BLISS-SC en pacientes con lupus eritematoso sist\u00e9mico (LES) activo. Estos resultados, que se han presentado en la Reuni\u00f3n Anual del American [&hellip;]","og_url":"https:\/\/lupusgalicia.org\/?p=1381","og_site_name":"Asociaci\u00f3n Galega de Lupus","article_publisher":"https:\/\/www.facebook.com\/LupusGalicia\/","article_published_time":"2015-11-12T16:05:22+00:00","og_image":[{"url":"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-300x159.jpg","type":"","width":"","height":""}],"author":"Agal","twitter_card":"summary_large_image","twitter_creator":"@LupusGalicia","twitter_site":"@LupusGalicia","twitter_misc":{"Escrito por":"Agal","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lupusgalicia.org\/?p=1381#article","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/?p=1381"},"author":{"name":"Agal","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665"},"headline":"GSK anuncia resultados positivos de Benlysta\u00ae en su fase III","datePublished":"2015-11-12T16:05:22+00:00","mainEntityOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=1381"},"wordCount":428,"commentCount":0,"publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=1381#primaryimage"},"thumbnailUrl":"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-300x159.jpg","keywords":["Belibumab","Benlysta","Tratamientos"],"articleSection":["Investigaci\u00f3n","Lupus Internacional"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lupusgalicia.org\/?p=1381#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lupusgalicia.org\/?p=1381","url":"https:\/\/lupusgalicia.org\/?p=1381","name":"GSK anuncia resultados positivos de Benlysta\u00ae en su fase III - Asociaci\u00f3n Galega de Lupus","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=1381#primaryimage"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=1381#primaryimage"},"thumbnailUrl":"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-300x159.jpg","datePublished":"2015-11-12T16:05:22+00:00","breadcrumb":{"@id":"https:\/\/lupusgalicia.org\/?p=1381#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lupusgalicia.org\/?p=1381"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/?p=1381#primaryimage","url":"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-300x159.jpg","contentUrl":"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2015\/11\/3078a28c6feb1f9e408af5e3811698e1_XL-300x159.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/lupusgalicia.org\/?p=1381#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/lupusgalicia.org\/"},{"@type":"ListItem","position":2,"name":"GSK anuncia resultados positivos de Benlysta\u00ae en su fase III"}]},{"@type":"WebSite","@id":"https:\/\/lupusgalicia.org\/#website","url":"https:\/\/lupusgalicia.org\/","name":"Asociaci\u00f3n Galega de Lupus","description":"Trabajando para y por las personas con Lupus","publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lupusgalicia.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/lupusgalicia.org\/#organization","name":"Asociaci\u00f3n Galega de Lupus","url":"https:\/\/lupusgalicia.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","width":2560,"height":2522,"caption":"Asociaci\u00f3n Galega de Lupus"},"image":{"@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LupusGalicia\/","https:\/\/x.com\/LupusGalicia","https:\/\/www.instagram.com\/lupusgalicia\/"]},{"@type":"Person","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665","name":"Agal","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","caption":"Agal"},"description":"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...","sameAs":["http:\/\/www.lupusgalicia.org"],"url":"https:\/\/lupusgalicia.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/1381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1381"}],"version-history":[{"count":1,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/1381\/revisions"}],"predecessor-version":[{"id":1383,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/1381\/revisions\/1383"}],"wp:attachment":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}